Begin typing your search above and press return to search.
Volume: 3 Issue: 2 December 2005

FULL TEXT

Successful ABO-Incompatible Liver Transplantation with Pre- and Postoperative Plasmapheresis, Triple Immunosuppression, and Splenectomy for Fulminant Hepatic Failure

Fulminant hepatic failure continues to be a challenge to hepatologists and surgeons. Because of the rapid deterioration in the clinical condition of patients with fulminant hepatic failure and the scarcity of available grafts, an ABO-incompatible liver donor may be the only choice for a patient with life-threatening hepatic insufficiency. Here, we report a patient with fulminant hepatic failure who received an ABO-incompatible liver transplantation who was treated with pre- and posttransplantation double-volume total plasma exchange, splenectomy, and triple immunosuppression (tacrolimus, mycophenolate mofetil, and prednisone) in July 2003. At 26 months’ follow-up, the patient’s postoperative course has been uneventful. Using protocols aimed at removing existing isohemagglutinins and reducing further antibody production, ABO-incompatible liver transplantation may be performed as a life-saving procedure in patients with fulminant hepatic failure.


Key words : ABO-incompatible, liver transplantation, plasmapheresis, splenectomy

Fulminant hepatic failure is a rapidly progressive and often fatal syndrome affecting patients with previously healthy livers. It is not a common condition but represents 9% of all transplantations in Europe and 12% in the Nordic countries as one of the major indications for liver transplantation [1]. The clinical presentation varies widely and is usually complicated by cerebral edema, renal impairment, sepsis, and multiorgan failure.

Liver transplantation has dramatically changed the management of patients with fulminant hepatic failure, but the scarcity of available grafts and the rapid deterioration frequently observed in these patients increase the possibility that the transplant team will have to accept marginal donor organs, in some cases, even ABO-incompatible livers [2-4].

ABO-incompatible liver transplantation has been associated with significantly higher incidences of antibody-mediated rejections, lower patient and graft survival rates, and a high risk of hepatic artery thrombosis and biliary stricture compared with ABO-compatible transplants [5-8]. Previous reports have demonstrated that multiple plasmapheresis before transplantation can effectively reduce preformed antibodies to the donor-blood group antigen that bind to the vascular endothelium in the graft [9].

We report a patient with fulminant hepatic failure who received an ABO-incompatible liver transplantation with pretransplantation and posttransplantation double-volume total plasma exchange, splenectomy, and triple immunosuppression (tacrolimus, mycophenolate mofetil, and prednisone) in July 2003.

Case Report
A 23-year-old man with blood type B who had been hospitalized for elevated fever of unknown origin presented with fulminant hepatic failure with a progressive rise in liver enzymes. Owing to the deterioration of his clinical status, he underwent pretransplantation double-volume total plasma exchange and was placed on the National Transplant Coordination Center (Ankara, Turkey) list for an urgent liver transplantation. Forty-eight hours after being placed on the list, the first available donor in a nationwide search was of blood type A, and our patient’s level of unconsciousness led us to accept an ABO-incompatible organ. Orthotopic liver transplantation and splenectomy were performed. The systemic triple immunosuppressive regimen included tacrolimus, methylprednisolone, and mycophenolate mofetil. Bolus IV methylprednisolone was used for the first 7 days posttransplantation (1 g intraoperatively, 500 mg on day 2, 250 mg on day 3, tapered to 30 mg oral prednisolone on day 8 ). Target trough levels of tacrolimus were 15-20 ng/mL on days 0-7, 10-15 ng/mL on days 8-21, and 5-10 ng/mL thereafter. Mycophenolate mofetil was given orally (1 g b.i.d.). In addition to the systemic antirejection therapy shown above, high-dose polyvalent intravenous gamma-globulin (5 g q.d.) was administered during postoperative days 1-5.

Double-volume total plasma exchange was continued immediately after the transplantation on days 1-10 with AB donor plasma. Initial anti-A isoagglutinin titers before total plasma exchange were 1:128 and remained below 1:4 throughout the first 10 postoperative days (Figure 1).

A severe episode of cellular rejection that was responsive to pulse steroid treatment occurred on posttransplant day 12. Six weeks after the transplantation, the patient’s clinical status deteriorated, with the patient displaying a high fever, trembling, and leukocytosis. Blood tests were positive for cytomegalovirus by PCR analysis and pp65 antigen. He was diagnosed as having cytomegalovirus infection, which was responsive to parenteral ganciclovir (5 mg/kg b.i.d. for 14 days). Later, a biliary leak from the T-tube insertion point and bile collection in the subhepatic area occurred, for which percutaneous placement of a drainage catheter and prolonged T-tube follow-up were required. Following T-tube removal, the patient was discharged. His postoperative course (assessed on day 70) has been uneventful, and he has remained healthy during 18 months of follow-up.

Discussion

Fulminant hepatic failure, which may be caused by a variety of factors, continues to challenge hepatologists and surgeons alike. The underlying liver disease may have a major impact on outcome and generally runs a rapid course with a high mortality rate. In randomized clinical studies, many artificial liver support devices have been examined, but none has been demonstrated effective enough to save lives. These systems are based on detoxification functions, using membranes and adsorbents, which can remove the putative toxins associated with liver failure. They include systems with whole blood exchange, charcoal hemoperfusion, plasma exchange with hemoperfusion, and hemodiabsorption with powdered-activate charcoal (BioLogic-DT, Hemotherapies, San Diego, Calif, USA). However, the molecular adsorbent recirculating system (MARS, Teraklin, AG, Rostock, Germany), which is based on hemodiabsorption with albumin, has gained much attention [10, 11]. One recent metaanalysis concluded that MARS treatment had no significant survival benefit in patients with liver failure when compared with standard medical therapy, and that further, well-conducted randomized trials needed to be conducted to define the role of MARS in the treatment of patients with liver failure [12].

Owing to the rapid deterioration in their clinical condition, patients with fulminant hepatic failure are usually listed as needing urgent liver transplantation, which is accepted as the best available treatment option. However, the scarcity of available cadaveric donors of recipients’ matched ABO blood groups obligates the transplant team to consider using ABO-incompatible hepatic grafts in these patients.

Expression of ABO antigens has been shown by immunohistochemical techniques on the hepatic artery, portal vein, capillary, sinusoidal lining cells, and bile duct epithelium but not on the bile ductule or hepatocytes [13]. Since anti-ABO isohemagglutinins (anti-A and anti-B) can mediate hyperacute, or accelerate acute, rejection, significantly higher incidences of rejection, hepatic artery thrombosis, and biliary stricture have been reported in ABO-incompatible grafts compared with ABO-compatible ones [6-8, 14].

Several studies have emphasized that multiple regimens of plasmapheresis before transplantation, which are crucial to avoiding humoral rejection, effectively reduce the pretransplantation titers of these antibodies, especially in live-donor liver transplantation. By performing double-volume total plasma exchange with plasma that is ABO compatible with both the patient serum and the donor liver, 90% of the immunoglobulin (Ig) can be removed, whereas a single-volume exchange removes only 67% [9, 15-17].

Splenectomy concomitant with grafting is routinely done in ABO-incompatible kidney transplantation based on the experiences of Alexandre and colleagues [18]. These authors found that patients who retained their spleens lost their grafts, whereas patients receiving splenectomy had no graft loss. Ishida and colleagues have shown that isohemagglutinin titers decreased to 1:4 in all patients and remained low during follow-up in 75% of transplantations after splenectomy in ABO-I kidney recipients [19].

Use of ABO-incompatible grafts for liver transplantation in highly urgent patients without preoperative total plasma exchange and splenectomy results in poor patient and graft survival rates [1, 5]. Encouraging results in ABO-incompatible liver transplantation with novel approaches, utilizing a combination of pre- and postoperative total plasma exchange, splenectomy, and enhanced immunosuppressive protocols with or without intraportal infusion therapies have been reported by various centers [3, 4, 20, 21].

Hanto and coworkers have reported a series of 14 patients receiving ABO-incompatible liver transplantation using total plasma exchange, splenectomy, and quadruple immunosuppression with actuarial 1-year patient and graft survival rates of 71.4% and 61.2%, respectively [20]. On the other hand, intraportal infusion therapy using continuous administration of gabexate mesylate, methylprednisolone, and prostaglandin E1 has been reported in 3 cases by Japanese centers as a novel approach in live-donor liver transplantation [4, 21].

The risk of viral reactivation is enhanced during acute rejection and increased immunosuppression following liver transplantation [22]. Although the seroprevalence of the donor was not provided, considering the recipient’s seropositivity for cytomegalovirus, prophylaxis with intravenous ganciclovir was given during the first 10 days of transplantation followed by oral acyclovir. The prophylaxis failed, however, and additional treatments with intravenous ganciclovir were required.

In our case, the patient received an ABO-incompatible graft and was treated utilizing pre- and posttransplant total plasma exchange, splenectomy, and triple immunosuppression. His postoperative course was uneventful, although he had severe cellular rejection and cytomegalovirus infection.

In conclusion, ABO-incompatible liver transplantations may be performed as a life-saving procedure in patients with fulminant hepatic failure utilizing protocols that remove existing isohemagglutinins and further reduce antibody production.


References:

  1. Bjoro K, Ericzon BG, Kirkegaard P, Hockerstedt K, Soderdahl G, Olausson M, et al. Highly urgent liver transplantation: possible impact of donor-recipient ABO matching on the outcome after transplantation. Transplantation 2003: 75: 347-353
  2. Chui AK, Ling J, McCaughan GW, Painter D, Shun A, Dorney SF, et al. ABO blood group incompatibility in liver transplantation: a single-centre experience. Aust N Z J Surg 1997: 67: 275-278
  3. Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation. Transplantation 2003: 76: 1648-1649
  4. Sekido H, Matsuo K, Takeda K, Morioka D, Kubota T, Tanaka K, et al. Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success. Transplantation 2003: 75: 1605-1607
  5. Farges O, Kalil AN, Samuel D, Saliba F, Arulnaden JL, Debat P, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 1995: 59: 1124-1133
  6. Garcia-Valdecasas JC, Ordi J, Grande L, Fuster J, Lacy AM, Gonzalez FX, et al. Intrahepatic biliary lesions and ABO incompatibility after liver transplantation. Transplant Proc 1993: 25: 3110-3111
  7. Lo CM, Shaked A, Busuttil RW. Risk factors for liver transplantation across the ABO barrier. Transplantation 1994: 58: 543-547
  8. Sanchez-Urdazpal L, Sterioff S, Janes C, Schwerman L, Rosen C, Krom RA. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc 1991: 23: 1440-1441
  9. Kawagishi N, Ohkohchi N, Fujimori K, Orii T, Koyamada N, Kikuchi H, et al. Antibody elimination by apheresis in living donor liver transplant recipients. Ther Apher 2001: 5: 449-454
  10. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R. Albumin dialysis using the molecular adsorbent recirculating system. Curr Opin Nephrol Hypertens 2001: 10: 777-783
  11. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001: 12 Suppl 17: S75-S82
  12. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004: 10: 1099-1106
  13. Hayashi S, Noguchi K, Yagihashi A, Starzl TE, Iwaki Y. Expression of blood group antigen (A, B, H, Le(a), Le(b)) on liver allografts. Transplant Proc 1992: 24: 2567-2568
  14. Farges O, Nocci Kalil A, Samuel D, Arulnaden JL, Bismuth A, Castaing D, et al. Long-term results of ABO-incompatible liver transplantation. Transplant Proc 1995: 27: 1701-1702
  15. Hashimoto T, Kondo S, Suzuki T, Nakamura T, Shimizu Y, Nakamura Y, et al. Strategy for ABO-incompatible living-related liver transplantation. Transplant Proc 2000: 32: 2104-2106
  16. Mor E, Skerrett D, Manzarbeitia C, Sheiner PA, Schwartz ME, Emre S, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995: 59: 986-990
  17. Yandza T, Lambert T, Alvarez F, Gauthier F, Jacolot D, Huault G, et al. Outcome of ABO-incompatible liver transplantation in children with no specific alloantibodies at the time of transplantation. Transplantation 1994: 58: 46-50
  18. Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987: 19: 4538-4542
  19. Ishida H, Koyama I, Sawada T, Utsumi K, Murakami T, Sannomiya A, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000: 70: 681-685
  20. Hanto DW, Fecteau AH, Alonso MH, Valente JF, Whiting JF. ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: evidence for accommodation. Liver Transpl 2003: 9: 22-30
  21. Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002: 73: 1959-1961
  22. Halme L, Hockerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003: 75: 1853-1858


Volume : 3
Issue : 2
Pages : 390 - 394


PDF VIEW [106] KB.

Gulhane Military Medical Academy, Departments of 1Surgery, 2Internal Medicine, and 3Anesthesiology, Ankara, Turkey
4Department of Surgery, Gazi University, Ankara, Turkey
5Department of Surgery, University of Wisconsin Medical School, Division of Organ Transplantation, Madison, WI, USA
Address reprint requests to: Gokhan Yagci, Gulhane Military Medical Academy, Department of Surgery, Gn.Tevfik Saglam Cad. Etlik, Ankara, Turkey 06018
Phone: 00 90 312 304 5113
Fax: 00 90 312 304 5100
E-mail: gyagci@gata.edu.tr